ENGLEWOOD, Colo., Dec. 13, 2021 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical
company focused on the advancement of immunology-based therapies
for prevalent inflammatory conditions, today announced that it has
entered into definitive agreements with institutional investors for
the purchase and sale of 25,000,000 shares of the Company's common
stock ( the "Shares") and warrants to purchase 15,000,000 shares of
the Company's common stock (the "Warrants" and, together with the
Shares, the "Securities") at a combined purchase price of
$0.90 per Share in a registered
direct offering. The Warrants will have an exercise price
of $1.10 per share, will be exercisable immediately and
will expire five years from the date of issuance. The closing of
the offering is expected to occur on or about December 15,
2021, subject to the satisfaction of customary closing
conditions.
![Ampio Pharmaceuticals Logo. (PRNewsFoto/Ampio Pharmaceuticals, Inc.) (PRNewsfoto/Ampio Pharmaceuticals, Inc.) Ampio Pharmaceuticals Logo. (PRNewsFoto/Ampio Pharmaceuticals, Inc.) (PRNewsfoto/Ampio Pharmaceuticals, Inc.)](https://mma.prnewswire.com/media/479965/Ampio_Pharmaceuticals_Logo.jpg)
A.G.P./Alliance Global Partners is acting as the sole placement
agent for the offering.
The gross proceeds to Ampio, before deducting placement agent
fees and other expenses, are expected to be $22.5 million. Ampio intends to use the net
proceeds from this offering for general corporate purposes, which
may include working capital and the conduct of clinical trials.
The Securities described above will be offered by the Company
pursuant to an effective "shelf" registration statement on Form S-3
(File No. 333-237723) previously filed with the Securities and
Exchange Commission (the "SEC") on April 16,
2020, and declared effective by the SEC on May 6, 2020, and the base prospectus contained
therein. A final prospectus supplement and the accompanying
base prospectus relating to and describing the offering will be
filed with the SEC. Electronic copies of the final prospectus
supplement may be obtained, when available, from A.G.P./Alliance
Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212)
624-2060, or by email at prospectus@allianceg.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or
jurisdiction.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company
primarily focused on the advancement of immunology-based therapies
to treat prevalent inflammatory conditions for which there are
limited treatment options. Ampio's lead drug, Ampion™, is backed by
an extensive patent portfolio with intellectual property protection
extending through 2037 and may be eligible for 12-year FDA market
exclusivity upon approval as a novel biologic under the Biologics
Price Competition and Innovation Act (BPCIA).
Forward Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to the registered direct offering,
including statements related to the anticipated use of proceeds
from the offering and statements relating to the timing of closing
of the offering, and Ampion and its classification, all of which
are inherently subject to various risks and uncertainties.
These risks and uncertainties include Ampio's ability to
satisfy the closing conditions and consummate the transaction
described herein, as well as those risks and uncertainties detailed
from time to time in Ampio's filings with the Securities and
Exchange Commission, including without limitation, under Ampio's
Annual Report on Form 10-K and other documents filed with the
Securities and Exchange Commission. Ampio undertakes no obligation
to revise or update these forward-looking statements, whether as a
result of new information, future events or otherwise.
Investor and Media Contacts:
Tony Russo or Nic Johnson
Russo Partners
info@ampiopharma.com
tony.russo@russopartnersllc.com
nic.johnson@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-announces-pricing-of-22-5-million-registered-direct-offering-301442834.html
SOURCE Ampio Pharmaceuticals, Inc.